According to the Institute for Safe Medication Practices (ISMP), the generic name for Strattera is at risk of being confused with:

Rationale

Atomoxetine

According to the Institute for Safe Medication Practices (ISMP), the generic name atomoxetine (Strattera) is at risk of being confused with atorvastatin due to the similarity in spelling and pronunciation. Such look-alike or sound-alike (LASA) confusion can lead to medication errors if prescriptions are misread or misinterpreted.

A (atorvastatin) CORRECT

This is correct. ISMP specifically identifies atorvastatin as a medication that may be confused with atomoxetine, increasing the risk of dispensing or prescribing errors.

B (dapagliflozin) YOUR ANSWER

This is incorrect. Dapagliflozin, a diabetes medication, does not have a documented LASA risk with atomoxetine.

C (rivaroxaban) YOUR ANSWER

This is incorrect. Rivaroxaban, an anticoagulant, is not commonly confused with atomoxetine according to ISMP.

D (famotidine) YOUR ANSWER

This is incorrect. Famotidine, an H2 receptor antagonist, does not appear as a high-risk LASA confusion with atomoxetine.

Conclusion

Atomoxetine (Strattera) has been identified by ISMP as a drug with potential for LASA errors, particularly with atorvastatin. Awareness and careful verification are essential to prevent medication errors in prescribing and dispensing.

According to the Institute for Safe Medication Practices (ISMP), the generic name for Strattera is at risk of being confused with:

Atomoxetine

Related Questions

Related Quizzes

How familiar were you with this question?

Report an Issue

Rate this Practice Test